RegSeek vs Large CROs for Regulatory Consultant Sourcing
When a regulatory need is large or closely linked to clinical development, a major global contract research organisation (CRO) is an obvious option. IQVIA, Parexel, and ICON all provide strategic and operational regulatory services alongside broader clinical and development capabilities. MCRA, an IQVIA business, also combines MedTech regulatory consulting with clinical research, reimbursement, healthcare compliance, quality assurance, and related services. These organisations can be well suited to multinational programs and work that combines clinical and regulatory delivery.
However, a large CRO is only one provider model. It should not be the automatic choice. The same need might be better served by a global CRO, a specialist consulting firm, a boutique, or an experienced independent consultant. The sourcing task is to decide which model best fits the work and then engage the selected provider on suitable terms.
This is not a like-for-like comparison. A CRO performs regulatory services. RegSeek is an access and sourcing platform. It helps buyers define the need, identify and compare suitable external providers, and decide how to engage the selected provider. Depending on provider availability and the sourcing route, the options may include a large CRO as well as specialist firms, boutiques, and independent consultants.
RegSeek vs Large CROs: quick comparison
| Criteria | Large CRO Regulatory Consulting Arm | RegSeek |
|---|---|---|
| What it is | A provider that performs and delivers regulatory work, often at scale and alongside clinical or operational services. | A regulatory-specific sourcing and comparison workflow for identifying and assessing external providers. |
| Primary value | Scale, multinational reach, infrastructure, broad capabilities, and possible integration across workstreams. | Structured comparison against the same defined brief, controlled disclosure, and a choice of provider models. |
| Best for | Large, multi-country, operational, or integrated clinical-plus-regulatory programs. | Defining or sourcing a project or advisory need before committing to one provider model. |
| Fit assessment | The buyer assesses the proposed scope, named delivery team, relevant experience, and commercial terms directly. | The buyer compares approach, relevant experience, named team, timing, fees, and assumptions across responding providers. |
| Delivery model | Work may be delivered by CRO employees, affiliated entities, local partners, or subcontractors, depending on the engagement. | The selected provider performs the work. RegSeek supports sourcing, comparison, and the route to engagement rather than delivering the work itself. |
| Commercial structure | Pricing may include delivery fees, project management, quality oversight, systems, infrastructure, pass-through costs, and other commercial components. The treatment of third-party costs depends on the contract. | Shortlist & Connect is free to post, compare, and shortlist before payment to unlock selected providers. Assisted Sourcing and other paid services are priced separately, and project terms are agreed with the selected provider. |
| Confidentiality | The buyer usually approaches and engages the CRO directly, so identity and project context are disclosed during sales and procurement. | Requests can keep the company identity masked, with sensitive information and contact details revealed at a stage controlled by the buyer. |
| Relationship | A direct engagement with one provider, which may coordinate several internal and external delivery resources. | A sourcing workflow that may compare a large CRO, specialist firm, boutique, or independent, subject to provider availability and the sourcing route. |
| Best-fit use case | Delivering a large or integrated regulatory program after the buyer has confirmed the team and commercial model. | Running a controlled sourcing process before choosing and engaging the provider that best fits the need. |
When a CRO consulting arm works well
For the right type of work, a large CRO’s regulatory arm can be a strong choice and sometimes the natural one.
It works well for:
- Large, multinational programs. When regulatory work covers many countries and requires coordination at scale, a global CRO’s footprint and infrastructure can be difficult to match.
- Integrated clinical and regulatory delivery. When regulatory work sits alongside a clinical trial run by the same organisation, integration can reduce handoffs and align regulatory, operational, safety, and clinical workstreams.
- Regulatory operations at volume. Submission publishing, eCTD sequence management, lifecycle maintenance, and country-level regulatory operations can suit an organisation designed for high operational throughput.
- Breadth of services. A CRO may combine regulatory work with safety, clinical development, quality, reimbursement, and market access under one relationship.
- A single coordination point. For complex programs across several markets and disciplines, one main commercial relationship may reduce the coordination burden on the buyer.
A CRO consulting arm can therefore be well suited when the need is large, operational, multinational, or closely linked to a clinical program. The buyer should still confirm that the proposed team and delivery model fit the work.
What you are actually buying: scale and the named team
The main point to understand is the difference between the CRO brand and the team assigned to your engagement. A CRO’s reputation reflects its scale, systems, and overall track record. The actual project, however, is delivered by named individuals. Strategic depth can vary by therapeutic area, product class, jurisdiction, authority, and which people are available when the work starts.
Your diligence should therefore focus on the proposed delivery team, not only on the logo. For work that requires senior regulatory judgment, such as pathway strategy, evidence interpretation, or preparation for an authority meeting, ask whether the named senior person has recent and directly relevant experience.
A buyer that relies mainly on the CRO brand may receive a capable team that is still less specialised than the question requires. A specialist firm or senior independent consultant may offer more directly relevant judgment for a focused assignment. A large CRO may offer stronger infrastructure and broader coverage for a complex program.
Scale is a real advantage for operations, coordination, and reach. It does not guarantee the exact expertise needed for every regulatory question. Both points can be true, which is why the decision should be based on the defined need and the proposed team.
Who will actually perform the work?
A large CRO may not perform every part of an engagement only through its own employees. Depending on the jurisdiction, required expertise, internal capacity, and contracted delivery model, it may use affiliated entities, local partners, smaller specialist consultancies, independent consultants, or other subcontractors.
This is not automatically a disadvantage. A CRO can give the buyer one main contractual and coordination relationship while bringing together several capabilities, markets, and workstreams. Its project management, quality systems, contracting infrastructure, insurance, technology, and oversight may add genuine value.
The delivery chain should still be clear. Buyers should ask:
- Which named individuals will perform each part of the work?
- Are they CRO employees, employees of an affiliated entity, local partners, independent consultants, or other external subcontractors?
- Which activities may be subcontracted after the engagement starts?
- Does the buyer have approval or notification rights when subcontractors or named team members change?
- Who reviews, quality-controls, and takes responsibility for externally delivered work?
- Are third-party costs passed through at cost, marked up, or included in a bundled fee?
- What separate project-management, quality, technology, or coordination charges apply?
When a CRO sits between the buyer and an external specialist who performs part of the work, the total price may include more than the specialist’s fee. It may also include CRO project management, quality oversight, contracting, systems, infrastructure, risk allocation, and commercial margin. Directly engaging an equivalent specialist may therefore cost less for a focused assignment.
That result should not be assumed. Third-party costs may be passed through at cost, included in a broader fee, or marked up, depending on the contract. A CRO may also achieve scale efficiencies, take on meaningful delivery risk, or provide coordination that the buyer would otherwise have to manage. The key question is whether each extra delivery and commercial layer adds value that is proportionate to its cost.
Where CRO-only sourcing can fall short
Considering only a CRO arm, without comparing other provider models, can have limits.
It can be a scale mismatch. For a focused question or tightly defined deliverable, a large organisation’s processes, governance, and overhead may be more than the work needs. A specialist firm or senior independent may offer a more proportionate model.
Strategic depth varies. Operational scale does not always mean deep strategic expertise in every niche, product class, pathway, or authority interaction. The named team matters more than the size of the corporate service catalogue.
The delivery chain may not be clear from the brand. A proposal may be delivered entirely by CRO employees, through affiliated entities, or partly through local partners and subcontractors. Buyers should assess team status, subcontracting rights, quality oversight, accountability, and how third-party costs are treated.
Comparison is harder without alternatives. If a buyer approaches one CRO directly and does not ask other provider models to respond to the same brief, it is difficult to know whether the CRO is the best fit or simply the most visible option.
Confidentiality during selection works differently. Directly approaching a large provider may reveal company identity, product context, or timing before the buyer knows whether that provider is suitable. This can matter for a planned submission, authority interaction, or lifecycle change; M&A, licensing, partnering, or investment diligence; remediation; or sensitive product and compliance issues.
These points are not a criticism of CROs. CROs can be excellent for the work they are designed to handle. The point is to choose the provider and delivery model deliberately rather than by default.
What RegSeek adds
RegSeek adds a regulatory-specific sourcing layer before provider selection. For a defined project, Shortlist & Connect allows a buyer to submit a structured confidential request and compare provider interest before paying to unlock selected providers. If the need is complex, sensitive, multi-market, or not yet clearly scoped, RegSeek-Assisted Sourcing can help refine the brief, identify suitable providers, conduct confidential outreach, prepare a curated shortlist, and support proposal comparison and selection.
Buyers control how much information is shared at each stage. Company identity can remain masked while eligible providers review the brief. Depending on the sourcing route, a request can be shared with relevant providers or limited to selected invited profiles.
Providers can then submit structured expressions of interest (EOIs) against the same request. The buyer can compare:
- Proposed approach and scope.
- Relevant experience and the named delivery team.
- Who will perform the work and whether affiliates or subcontractors are proposed.
- Fee estimates and commercial assumptions, including how third-party costs are treated.
- Timeline and earliest start date.
- Product, market, pathway, and authority fit.
- Dependencies, risks, assumptions, and limitations.
This makes the provider-model decision explicit. Depending on provider availability and the sourcing route, the comparison may include a large CRO, specialist firms, boutiques, and independent consultants. When a relevant CRO participates or is approached through RegSeek-Assisted Sourcing, the buyer can assess its proposed team, delivery chain, and commercial model alongside alternatives responding to the same brief.
RegSeek does not replace the provider that performs the work. It helps the buyer define, source, compare, and select that provider while keeping greater control over disclosure and the basis for comparison.
Best path: a CRO, RegSeek, or both?
Use a large CRO when the need is multinational, operational, integrated with a clinical program, or broad enough to benefit from substantial infrastructure and coordination. Before proceeding, confirm that the proposed team, delivery chain, and commercial structure fit the work.
Use RegSeek when you want to decide which provider model fits before making a commitment. It can support a focused or specialised search, comparison against the same brief, and controlled disclosure during selection. The available comparison will depend on which providers participate and the sourcing route used.
Use both when the program has scale but the provider-model decision still needs to be tested. RegSeek can run a confidential sourcing process. If a suitable CRO participates or is approached through RegSeek-Assisted Sourcing, the buyer can assess it alongside specialist firms and independent consultants. The selected provider then performs the work.
Choosing the right provider model and delivering the engagement are connected but different tasks. A CRO is one delivery option. RegSeek is designed to help the buyer define the need and select the right option.
Choose the right sourcing path
If the regulatory project is already defined, use Shortlist & Connect to submit a confidential request, receive structured expressions of interest, compare provider fit, and shortlist before paying to unlock selected providers.
If the need is complex, confidential, multi-market, or not yet clearly scoped, RegSeek-Assisted Sourcing can help refine the brief, identify and approach suitable providers confidentially, and support shortlist and proposal comparison.
For a focused regulatory question rather than a broader project, Written Regulatory Advice or a Regulatory Expert Call may be the more suitable route.
Submit a Regulatory Request or review how RegSeek pricing works.
FAQ
Is RegSeek an alternative regulatory consulting provider to a CRO?
No. A CRO performs regulatory consulting and operational work. RegSeek helps buyers access, source, compare, and select external regulatory providers. The provider selected through RegSeek performs the project or advisory work.
Can a CRO subcontract regulatory work?
Yes, depending on the contract and delivery model. A CRO may use affiliated entities, local partners, smaller specialist consultancies, independent consultants, or other subcontractors. Buyers should ask who will perform the work, what approval rights apply, how quality and accountability are managed, and how third-party costs are treated.
Is a CRO always more expensive than engaging a specialist directly?
No. A CRO’s total price may include project management, quality oversight, systems, coordination, risk allocation, and commercial margin as well as specialist delivery costs. Direct engagement can therefore cost less for some focused assignments. However, third-party costs may be passed through at cost, bundled, or marked up. The CRO may also provide coordination or risk management that the buyer would otherwise need to supply. Compare the full scope and value of the proposed delivery model.
When should a buyer choose a large CRO?
A large CRO can be a strong choice for multinational, integrated, operationally intensive, or high-volume programs. This is especially true when clinical, regulatory, safety, quality, and market-access capabilities must work together. The buyer should still confirm the named team, delivery chain, relevant experience, and commercial assumptions.
Can RegSeek guarantee access to a particular CRO?
No. Participation depends on availability, relevance, eligibility, and the sourcing route. RegSeek can help identify and compare suitable provider models. RegSeek-Assisted Sourcing may also approach relevant providers confidentially, but it cannot guarantee that a particular organisation will participate or accept an engagement.
Sources and Further Reading
- IQVIA, Regulatory Consulting and Global Regulatory Affairs Services.
- Parexel, Global Regulatory Submissions and Outsourcing.
- ICON, Regulatory Affairs.
- MCRA, MedTech CRO and Advisory Services.
- Parexel, Supplier Code of Conduct (including supplier-subcontractor governance requirements).
- RegSeek, Provider participation and sourcing workflows and How pricing works.
Need help with a similar regulatory sourcing decision? Submit a confidential brief →